Skip to main content
SpringerLink
Log in

Atrofia vulvo-vaginale (AVV): marcatore di invecchiamento femminile?

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

L’atrofia vulvo-vaginale (AVV), condizione cronica progressiva emergente nella pratica clinica della post-menopausa per il suo notevole impatto sulla sessualità e sulla qualità della vita, necessita di una diagnosi tempestiva e di una terapia efficace e personalizzata. La nuova definizione di sindrome genito-urinaria della menopausa (GSM) ha dato notevole impulso alla comprensione dei meccanismi fisiopatologici alla base dei sintomi genitali (secchezza, bruciore, prurito, irritazione, perdite ematiche), sessuali (dispareunia e altre disfunzioni del desiderio, dell’eccitazione, dell’orgasmo) e urinari (disuria, frequenze, urgenza, infezioni urinarie ricorrenti) che coinvolgono sia fattori ormonali, sia fattori connessi al fenomeno dell’avanzare dell’età.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Simon JA, Goldstein I, Kim NN et al. (2018) The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 25:837–847

    Article  PubMed  Google Scholar 

  2. Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522

    Article  CAS  PubMed  Google Scholar 

  3. Simon JA, Davis SR, Althof SE et al. (2018) Sexual well-being after menopause: an international menopause society white paper. Climacteric. https://doi.org/10.1080/13697137.2018.1482647

    Article  PubMed  Google Scholar 

  4. Portman DJ, Gass ML, the Vulvovaginal Atrophy Terminology Consensus Conference Panel (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Menopause 21:1063–1068

    Article  PubMed  Google Scholar 

  5. Cagnacci A, Carbone MM, Palma F, the AGATA study (2016) Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause 23:1139–1145

    Article  PubMed  Google Scholar 

  6. Palacios S, Nappi RE, Bruyniks N et al. the EVES Study Investigators (2018) The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 21:286–291

    Article  CAS  PubMed  Google Scholar 

  7. Mac Bride MB, Rhodes DJ, Shuster LT (2010) Vulvo-vaginal atrophy. Mayo Clin Proc 85:87–94

    Article  Google Scholar 

  8. Lindau ST, Schumm LP, Laumann EO et al. (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357:762–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lang K, Alexander IM, Simon J et al. (2015) The impact of multimorbidity on quality of life among midlife women: findings from a US nationally representative survey. J Womens Health (Larchmt) 24:374–383

    Article  Google Scholar 

  10. Constantine GD, Bruyniks N, Princic N et al. (2014) Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. Curr Med Res Opin 30:143–148

    Article  PubMed  Google Scholar 

  11. Nappi RE (2007) New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric 10:105–108

    Article  PubMed  Google Scholar 

  12. Shifren JL (2018) Genito-urinary syndrome of menopause. Clin Obstet Gynecol 61:508–516

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Ostetrica e Ginecologica, IRCCS Policlinico S. Matteo, Università degli Studi di Pavia, Piazzale Golgi 2, 27100, Pavia, Italia

    Ellis Martini, Margherita Rossi, Laura Cucinella, Lara Tiranini, Silvia Martella, David Bosoni, Emanuela Brambilla, Alessandro Kunder Franco, Chiara Cassani & Rossella E. Nappi

Authors
  1. Ellis Martini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margherita Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Cucinella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lara Tiranini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia Martella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Bosoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emanuela Brambilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alessandro Kunder Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chiara Cassani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rossella E. Nappi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rossella E. Nappi.

Ethics declarations

Conflitti di interesse

Gli autori Ellis Martini, Margherita Rossi, Laura Cucinella, Lara Tiranini, Silvia Martella, David Bosoni, Emanuela Brambilla, Alessandro Kunder Franco, Chiara Cassani e Rossella E. Nappi dichiarano di non avere nessun conflitto di interesse nella stesura di questo articolo. La prof.ssa Nappi ha collaborato negli ultimi due anni con le seguenti aziende per ricerca, consulenza e relazioni a convegni: Bayer-Schering Pharma, Endoceutics, Exceltis, Gedeon-Richter, HRA Pharma, Merck Sharp & Dohme, Novo Nordisk, Pfizer Inc., Shionogi Limited and Teva Women’s Health Inc/Theramex.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Francesco Trimarchi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 29 kB)

(DOC 27 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martini, E., Rossi, M., Cucinella, L. et al. Atrofia vulvo-vaginale (AVV): marcatore di invecchiamento femminile?. L'Endocrinologo 19, 301–306 (2018). https://doi.org/10.1007/s40619-018-00487-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-00487-9

Parole chiave

Search

Navigation